{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+Candidate+%234",
    "query": {
      "intervention": "Vaccine Candidate #4"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 69,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+Candidate+%234&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T18:54:08.753Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06907511",
      "title": "Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pandemic Influenza Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Pandemic flu H5 HA mRNA SD2 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 720,
      "start_date": "2025-04-17",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 13,
      "location_summary": "La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06907511"
    },
    {
      "nct_id": "NCT05992935",
      "title": "Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Norovirus Acute Gastroenteritis"
      ],
      "interventions": [
        {
          "name": "mRNA-1403",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1405",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1407,
      "start_date": "2023-08-25",
      "completion_date": "2026-09-22",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 14,
      "location_summary": "Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05992935"
    },
    {
      "nct_id": "NCT01385189",
      "title": "Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hookworm Infection",
        "Hookworm Disease"
      ],
      "interventions": [
        {
          "name": "10 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "100 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-05",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2025-01-06",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01385189"
    },
    {
      "nct_id": "NCT04713553",
      "title": "A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Infection",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2.B.1.351",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 1574,
      "start_date": "2021-02-15",
      "completion_date": "2021-07-22",
      "has_results": true,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 17,
      "location_summary": "Oakland, California • Milford, Connecticut • Hialeah, Florida + 13 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04713553"
    },
    {
      "nct_id": "NCT03014310",
      "title": "H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Avian Influenza"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "MF59",
          "type": "DRUG"
        },
        {
          "name": "Monovalent Influenza A/H5N8 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 388,
      "start_date": "2017-01-09",
      "completion_date": "2018-12-19",
      "has_results": false,
      "last_update_posted_date": "2024-09-23",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014310"
    },
    {
      "nct_id": "NCT00110279",
      "title": "Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza",
        "Virus Diseases"
      ],
      "interventions": [
        {
          "name": "H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2005-06",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2008-01-21",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110279"
    },
    {
      "nct_id": "NCT02151344",
      "title": "Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Virus, H7N9 Subtype"
      ],
      "interventions": [
        {
          "name": "H7N9 A/Anhui/13 ca influenza virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated subvirion H7N9 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-05",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02151344"
    },
    {
      "nct_id": "NCT02052934",
      "title": "Safety of Sublingual dmLT for ETEC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroenteritis Escherichia Coli"
      ],
      "interventions": [
        {
          "name": "Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 80,
      "start_date": "2014-03-10",
      "completion_date": "2016-11-02",
      "has_results": false,
      "last_update_posted_date": "2019-01-28",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052934"
    },
    {
      "nct_id": "NCT03820414",
      "title": "Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Zoster",
        "Varicella Zoster"
      ],
      "interventions": [
        {
          "name": "CRV 101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Curevo Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 90,
      "start_date": "2019-01-03",
      "completion_date": "2020-04-30",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03820414"
    },
    {
      "nct_id": "NCT01979406",
      "title": "A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anthrax Infection"
      ],
      "interventions": [
        {
          "name": "AVA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad4-PA-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad4-PA-GPI-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 120,
      "start_date": "2013-11",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-19T18:54:08.753Z",
      "location_count": 4,
      "location_summary": "Kansas City, Kansas • Silver Spring, Maryland • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01979406"
    }
  ]
}